Vendor, San Diego, CA
Milecell Biotechnology Inc.
UEI KLF8HJ4A4UD3
1 award and $24,750 obligated between September 9, 2026 and September 9, 2026, 0% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| In-Vitro Diagnostic Substance ManufacturingNAICS 325413 | $24,750 |
How it wins
Awards by competition, set-aside and type.
| Competed Under SAP | 1 |
| Purchase Order | 1 |
Hear when Milecell Biotechnology Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Milecell Biotechnology Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $24,750
- Soonest
- December 31, 2026
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling in-vitro diagnostic substance manufacturing to Food and Drug Administration, by dollars.
| Remel Inc.Lenexa, KS | $3,237,392 |
| Alomone Lab Ltd.Jerusalem | $41,184 |
| R-Biopharm, Inc.Washington, MO | -$61 |
| Bio-Techne CorporationMinneapolis, MN | -$12,996 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75F40126P00211Purchase Order, September 9, 2026, Competed Under SAP, 1 offers | FDA Office of Acq Grant SVCSFood and Drug Administration | Primary Human Trophoblast CellsNAICS 325413, PSC 6810 | $24,750 |
- Places of performance
- California
- Product and service codes
- 6810 Chemicals
- Transactions
- 1 across 1 awards